Teon Therapeutics is a private biopharma start-up developing a portfolio of single-target small molecules that affect metabolic signaling pathways in the tumor microenvironment. Our pipeline includes synergistic biological targets, combining first-in-class and best-in-class candidates. Teon's lead program is an A2BR antagonist that is built upon the shortcomings of 1st-generation adenosine candidates and will enter Phase 1b trials in 2021. Our experienced leadership team is executing a tried-and-true strategy espoused by Gilead - develop high-specificity, single-target therapeutics.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
TT-702 (A2BR antagonist)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):